Anixa Biosciences Inc (ANIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.07+0.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Anixa is developing cancer and infectious disease therapies. It showed good patient survival in trials. Losses are shrinking with EPS improving from -$0.38 to -$0.31. The stock recently gained 14% in two months.
Anixa is still losing money with no revenue. Clinical trials face legal issues. EPS remains negative at -$0.31 next year. The company has high risk and no clear profit path.
The market has no clear consensus or price target. Estimates show ongoing losses. Our view sees some improvement but still high risk.
Breaks if: trial results fail or regulatory approvals are denied
Breaks if: EPS does not improve beyond -0.31 USD per share by FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is in a high-risk sector, specifically within healthcare. The current thesis state is cautious, as the company is loss-making and recent performance has been neutral, indicating uncertainty in its future trajectory.
The market appears to have low expectations for ANIX, reflecting its loss-making status and the high-risk nature of its industry. Investors may be pricing in the possibility of continued challenges, especially given recent litigation events.
Fundamentals are expected to remain under pressure due to the company's loss-making status and mixed recent performance. The management is stable, but the high miss probability in a volatile sector adds to the uncertainty.
The future of ANIX hinges on broader healthcare sector performance, particularly the results of major players like VRTX, REGN, and ARGX. Additionally, economic indicators such as job reports could significantly impact investor sentiment and the company's performance.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: litigation causes major delays or financial harm
Over the next 1-3 years, ANIX faces a challenging path with high risks and mixed signals from the market. Not investment advice.